Pfizer, Lilly, Sanofi, Amgen And Others Implicated In Indian Clinical Trial Compensation Investigation; Are Ethics Committees To Blame?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's Health Ministry is calling on multinational drug companies operating in India - including Pfizer Inc., Eli Lilly & Co., Amgen Inc., Bristol-Myers Squibb Co., Boehringer Ingelheim GMBH, Sanofi, and Quintiles Transnational Corp. - to explain why they have not provided compensation to the families of 26 patients who died during clinical trials in the last year. A recent health ministry investigation found that out of 671 cases of reported deaths allegedly involving clinical trials - and involving as many as 44 companies - only three were compensated, but companies suggest regulators should look to India's ethics committees for answers
You may also be interested in...
Patient Safety First: Indian Regulator Takes Steps To Tighten Grip Over Site Inspections, Ensure Data Credibility
MUMBAI - As India moves rapidly to become an integral part of large-scale global clinical trials, the Central Drugs Standard Control Organization under the Ministry of Health and Family Welfare has declared a set of new guidelines to ensure adequate safety of trial participants
Clinical Research Is Booming In India But Are There Enough IRBs?
MUMBAI - Over the past decade, India's clinical research industry has grown at a compound annual rate of 64 percent, zooming up from just $12 million in 2001 to an estimated billion-plus dollars by next year. But that meteoric rise may be putting pressure on Institutional Review Boards entrusted with approval of clinical trials and some industry experts are now asking for better controls over IRBs, or ethics review boards
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).